Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 31.77 CNY 0.47% Market Closed
Market Cap: 24.5B CNY
Have any thoughts about
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock under the Base Case scenario is 48.66 CNY. Compared to the current market price of 31.77 CNY, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
48.66 CNY
Undervaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3
P/S
P/S
Price to Sales
3
vs History
34
vs Industry
36
Median 3Y
3.1
Median 5Y
2.8
Industry
2.5
Forward
2.8
More Details
26.2
P/E
P/E
Price to Earnings
26.2
vs History
31
vs Industry
17
Median 3Y
26.2
Median 5Y
24.2
Industry
21.8
Forward
20.8
More Details
20.8
P/OCF
P/OCF
Price to OCF
20.8
vs History
69
vs Industry
6
Median 3Y
33
Median 5Y
26.2
Industry
16.1
More Details
15.8
P/FCFE
P/FCFE
Price to FCFE
15.8
vs History
93
vs Industry
6
Median 3Y
27.7
Median 5Y
29.9
Industry
23.8
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
22
vs Industry
19
Median 3Y
3.7
Median 5Y
3.1
Industry
2.1
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
34
vs Industry
36
Median 3Y
2.9
Median 5Y
2.5
Industry
2.7
Forward
2.5
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
52
vs Industry
29
Median 3Y
6.6
Median 5Y
6.3
Industry
5.2
More Details
28.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.4
vs History
39
vs Industry
10
Median 3Y
29.8
Median 5Y
27
Industry
13.5
Forward
14.8
More Details
28.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.4
vs History
39
vs Industry
13
Median 3Y
29.8
Median 5Y
27
Industry
16.8
Forward
20.7
More Details
19.2
EV/OCF
EV/OCF
Enterprise Value to OCF
19.2
vs History
66
vs Industry
6
Median 3Y
30.6
Median 5Y
24
Industry
15.2
More Details
21.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.7
vs History
95
vs Industry
5
Median 3Y
39.2
Median 5Y
31
Industry
19.3
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
39
vs Industry
24
Median 3Y
3
Median 5Y
2.8
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
24.5B CNY 3 26.2 28.4 28.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 90.3 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.9 11.6 15
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.6
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/E Multiple
Earnings Growth P/E to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average P/E: 31.7
26.2
66%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average EV/EBITDA: 416.5
28.4
154%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average EV/EBIT: 1 813
28.4
103%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.